3 terminated, 1 unknown. .
Follow Ourotech, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2 Biopsy - Kidney Cancer, Renal Cell Cancer Metastatic | Terminated | Ourotech, Inc. | 7 | 2024-06-19 | 2025-07-30 | |
| Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET) Biopsy - Breast Cancer, Triple Negative Breast Cancer | Unknown | Ourotech, Inc. | 30 | 2024-04-30 | 2024-04-03 | |
| Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO) Resection - Brain Tumor, Glioma, Malignant | Terminated | Ourotech, Inc. | 12 | 2023-10-12 | 2025-07-30 | |
| Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment Core needle biopsy - Triple Negative Breast Cancer, Triple Negative Breast Neoplasms | Terminated | Ourotech, Inc. | 34 | 2022-06-06 | 2025-07-30 |
Triple Negative Breast Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Ependymoma (1) · Glioblastoma (1) · Glioma (1) · Kidney Neoplasms (1) · Neoplasms (1) · Oligodendroglioma (1)
Biopsy (2) · Biopsy, Large-Core Needle (1)
United Kingdom (4)
Ekaterini Boleti (1) · Matt Williams, FRCR PhD (1) · Sheeba Irshad, MD PhD (1)